- Continue Shopping
- Your Cart is Empty
Hexoskin wins contract to bring Astroskin sensors to the Moon
November 26, 2024
Montréal, November 26th, 2024
The Canadian Space Agency (CSA) has announced that it has awarded a contract to Hexoskin (Carré Technologies Inc.), a company based in Montreal, to develop and adapt the Astroskin Bio-Monitor crew physiological monitoring system for Gateway, a space station that will orbit the Moon.
The first two elements of Gateway – the Power and Propulsion Element (PPE) and the Habitation and Logistics Outpost (HALO) – are set to launch together in 2027.
The Astroskin Bio-Monitor has been in operation on the International Space Station (ISS) since January 2019, when it was commissioned by Canadian astronaut David Saint-Jacques. It is currently used in four clinical trials in space focused on studying the cardiorespiratory system and the accelerated aging effect of microgravity on human physiology.
Astroskin wearable sensors are sent to space on a regular basis, with 20 space payloads delivered to ISS so far, and a first suborbital flight completed in November 2023 with American astronaut Kellie Gerardi on Virgin Galactic’s mission 5.
More than 20 astronauts have used Astroskin wearable sensors for clinical research in microgravity, including astronauts from the USA, Canada, Japan, UAE, and Italy. (Photo credits: CSA, ESA, NASA, JAXA, Axiom/Mark Pathy, UAE Space Agency)
Astroskin wearable health sensors are also used by a large number of medical researchers around the world to study a wide number of health conditions, from hypertension to sleep quality, in clinical trials, and for defense and aerospace applications.
About Hexoskin, Space Medicine, and Clinical Research
Hexoskin has been involved in space medicine since its first contract with CSA in 2011. The investment from CSA in space medicine research has been a major driver of growth in the early development of the company, during the development of the Hexoskin and Astroskin wearable sensor platforms. Hexoskin has supported hundreds of clinical research projects since, leading to over 250 peer-reviewed scientific publications, patents, and novel AI software for clinical applications, with a focus on cardiac and respiratory diseases. Hexoskin participated in the first cohort of the ASU/Mayo Clinic Medtech accelerator in 2019.
More info on the Gateway contract awarded to Hexoskin:
https://www.nasa.gov/mission/gateway/
More info on Astroskin:
https://www.hexoskin.com/astroskin
